- Home
- BBD vs ZTS Comparison
BBD vs ZTS Comparison
Compare BBD & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBD | ZTS |
|---|---|---|
| Founded | 1943 | 1952 |
| Country | Brazil | United States |
| Employees | 80348 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3B | 32.5B |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | BBD | ZTS |
|---|---|---|
| Price | $3.62 | $77.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | N/A | ★ $154.18 |
| AVG Volume (30 Days) | ★ 29.9M | 4.4M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.82% | 1.86% |
| EPS Growth | N/A | ★ 10.05 |
| EPS | N/A | ★ 1.42 |
| Revenue | N/A | ★ $9,467,000,000.00 |
| Revenue This Year | $70.86 | $5.63 |
| Revenue Next Year | $8.33 | $4.77 |
| P/E Ratio | ★ $9.20 | $53.55 |
| Revenue Growth | N/A | ★ 2.28 |
| 52 Week Low | $2.79 | $71.47 |
| 52 Week High | $4.30 | $160.48 |
Technical Indicators
Market Signals| Indicator | BBD | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 55.07 | 49.15 |
| Support Level | $3.41 | $73.42 |
| Resistance Level | $3.74 | $78.02 |
| Average True Range (ATR) | 0.08 | 1.95 |
| MACD | -0.00 | 0.46 |
| Stochastic Oscillator | 62.94 | 51.40 |
Price Performance
Historical ComparisonAbout BBD Banco Bradesco Sa
Banco Bradesco is Brazil's second-largest private bank, with about 10%-15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation, a private nonprofit institution focused on education. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.